PT939648E - Formulações de vacinas de rotavírus - Google Patents

Formulações de vacinas de rotavírus Download PDF

Info

Publication number
PT939648E
PT939648E PT97944477T PT97944477T PT939648E PT 939648 E PT939648 E PT 939648E PT 97944477 T PT97944477 T PT 97944477T PT 97944477 T PT97944477 T PT 97944477T PT 939648 E PT939648 E PT 939648E
Authority
PT
Portugal
Prior art keywords
vaccine formulations
rotavirus vaccine
rotavirus
formulations
vaccines
Prior art date
Application number
PT97944477T
Other languages
English (en)
Inventor
Carl J Burke
David B Volkin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621991.0A external-priority patent/GB9621991D0/en
Priority claimed from GBGB9714333.3A external-priority patent/GB9714333D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT939648E publication Critical patent/PT939648E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT97944477T 1996-09-26 1997-09-26 Formulações de vacinas de rotavírus PT939648E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2675496P 1996-09-26 1996-09-26
GBGB9621991.0A GB9621991D0 (en) 1996-10-22 1996-10-22 Rotavirus vaccine formulations
US4676097P 1997-05-16 1997-05-16
GBGB9714333.3A GB9714333D0 (en) 1997-07-07 1997-07-07 Rotavirus vaccine formulations

Publications (1)

Publication Number Publication Date
PT939648E true PT939648E (pt) 2008-01-11

Family

ID=27451542

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97944477T PT939648E (pt) 1996-09-26 1997-09-26 Formulações de vacinas de rotavírus

Country Status (10)

Country Link
EP (2) EP0939648B1 (pt)
JP (1) JP4653262B2 (pt)
AT (1) ATE377428T1 (pt)
AU (1) AU739916B2 (pt)
CA (1) CA2266486C (pt)
DE (1) DE69738271T2 (pt)
DK (1) DK0939648T3 (pt)
ES (1) ES2294801T3 (pt)
PT (1) PT939648E (pt)
WO (1) WO1998013065A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
US6436993B1 (en) 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
ATE327765T1 (de) * 1999-08-17 2006-06-15 Glaxosmithkline Biolog Sa Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AU2013224715B2 (en) * 2007-03-22 2015-10-08 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US8444991B2 (en) 2007-03-22 2013-05-21 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
DK2646052T3 (en) 2010-12-02 2017-07-17 Oncolytics Biotech Inc LYOPHILIZED VIRAL FORMULATIONS
TW201233802A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Liquid viral formulations
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
JP6050811B2 (ja) * 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アルミニウムアジュバントを含むhpvワクチン製剤およびその産生方法
EP2747777A4 (en) * 2011-08-25 2015-04-29 Brian Pulliam ROTAVIRUS PREPARATIONS WITH EXCESSIVE CALCIUMIONES AND HIGH VISCOSITY TO ENSURE VACCINITY OF THE VACCINE AT HIGH TEMPERATURES
JP6253161B2 (ja) * 2012-03-05 2017-12-27 デ スタート デル ネーデルランデン, ヴェルト. ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト, ベルジーン エン シュポルトDe Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport 乾燥された生物学的材料を安定化するための方法及び組成物
WO2016009381A2 (en) * 2014-07-18 2016-01-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
JP2019502685A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 熱安定性ロタウイルスワクチン製剤およびその使用方法
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
CA3149919A1 (en) * 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations
AU2020328159A1 (en) * 2019-08-09 2022-01-27 Valneva Se Single shot Chikungunya virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
WO1992001784A1 (en) * 1990-07-26 1992-02-06 The Wistar Institute Of Anatomy & Biology Rotavirus reassortant vaccine
US7150984B2 (en) * 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine

Also Published As

Publication number Publication date
JP4653262B2 (ja) 2011-03-16
AU4596397A (en) 1998-04-17
EP1891968A2 (en) 2008-02-27
EP0939648B1 (en) 2007-11-07
DE69738271D1 (de) 2007-12-20
WO1998013065A1 (en) 1998-04-02
CA2266486C (en) 2007-09-25
AU739916B2 (en) 2001-10-25
EP1891968A3 (en) 2008-09-03
ATE377428T1 (de) 2007-11-15
CA2266486A1 (en) 1998-04-02
JP2002500622A (ja) 2002-01-08
EP0939648A1 (en) 1999-09-08
DK0939648T3 (da) 2008-02-11
DE69738271T2 (de) 2008-08-28
ES2294801T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
PT939648E (pt) Formulações de vacinas de rotavírus
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
IL101290A0 (en) Vaccine formulations
TW289050B (pt)
HU9601466D0 (en) Adjuvants for viral vaccines
DK1047446T3 (da) Vaccinesammensætning til Herpes Simplex virus og fremgangsmåder til anvendelser deraf
HU9601462D0 (en) Adjuvants for viral vaccines
GB2301591A (en) Cytotoxic T-cell epitopes
NZ295238A (en) Immunogenic compositions characterised by the carrier being a hydrophobic solvent in the absence of a hydrophilic phase
HUP9701586A3 (en) Improved inactivated vaccines
AU3474593A (en) Hypericin treatment of vaccine agents for improved immunogenicity
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
AU4450696A (en) Enhanced immunogenic vaccine
GB9621991D0 (en) Rotavirus vaccine formulations
GB9614618D0 (en) Vaccine compositions
ZA978586B (en) Rotavirus vaccine formulations.
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
GB9714333D0 (en) Rotavirus vaccine formulations
GB9213882D0 (en) Live modified equine herpesvirus-4 vaccine
MX9705959A (es) Formulaciones para il-12.
ZA965334B (en) Controlled release formulations of ranitidine
ITRM910384A0 (it) Procedimento di preparazione di vaccini anti-influenzali e vaccini conesso ottenuti.
AUPM370894A0 (en) Improved adjuvant for vaccines
ITRM920074A1 (it) Procedimento per la preparazione di vaccini, e vaccini cosi' ottenibili.
ZA9711030B (en) Formulations and polymorphic forms of desferrioxamine and the preparation thereof.